Publication: Düşük frekanslı elektromanyetik alan ve paclitaxel uygulamasının meme kanserine etkisi
Abstract
Amaç: Çalışmamızda, meme kanserinin kemoterapatik tedavisinde yaygın olarak kullanılan anti-neoplastik ajan paklitakselin (PTX) etkinliğinin arttırılması amaçlanmıştır. PTX’ in çok düşük frekanslı elektromanyetik alan (ÇDF-EMA) ile birlikte kullanılmasının hücre canlılığı üzerindeki etkilerin belirlenmesi hedeflenmiştir.Gereç ve Yöntem: Çalışmamızda, insan meme kanseri hücre soyu MCF-7 (ATCC, HTB-22) ve kontrol olarak fare fibroblast hücre soyu L-929 (ATCC, CCL-1) kullanıldı. Hücreler %10 FBS, %1 antibiyotik ve 2 mM L-glutamin içeren DMEM besi yerinde, 37oC’de %5 CO2 içeren etüv içerisinde üretildi. ÇDF-EMA 15 cm çapında, 40 cm uzunluğunda, 400 sarımdan oluşan solenoid ile üretildi. PTX’ in IC50 değerlerinin belirlenmesinin ardından hücreler 24 saat süre ile ÇDF-EMA ve/ veya PTX’ e maruz bırakılarak canlılık ölçümleri yapıldı. Kaspaz değerleri Caspase-8 and Caspase-9 Multiplex Activity deney kiti ile ve kalsiyum değerleri Screen Quest FURA-2 kalsiyum deney kiti ile belirlendi.Bulgular: MCF-7 için; Kontrol grubuna göre ÇDF-EMA’ ya maruz kalan grupta %34,29 (±0,069-STD), PTX uygulaması yapılan grupta %53,5 (±0,033-STD), her iki etkenin bir arada kullanıldığı grupta ise %60,19 (±0,088-STD) oranında canlılıkta azalma görülmüştür. L-929 için; Kontrol grubuna göre ÇDF-EMA’ ya maruz kalan grupta %36,25 (±0,018-STD), PTX uygulaması yapılan grupta %46,27 (±0,115-STD), her iki etkenin bir arada kullanıldığı grupta %65,32 (±0,152-STD) oranında canlılıkta azalma görülmüştür. Kalsiyum ve Kaspaz ölçümlerinde canlılık ile uyumlu olarak ÇDF-EMA ve/ veya PTX uygulamalarında kontrole göre artış olduğu görülmüştür.Sonuç: Çalışmamızda ÇDF-EMA’ nın paklitaksel etkinliğini artırdığı saptanmıştır.
Objective: Treatment of breast cancer causes serious side effects which necessitates the investigation of alternative methods. This study aimed to increase the effectiveness of antineoplastic agent Paclitaxel (PTX) by co-application with Extremely Low Frequency Electromagnetic Field (ELF-EMF) that have been shown to induce apoptosis and decrease survival.Materials and Method: Breast cancer cell line MCF-7 (ATCC, HTB-22) and L-929 (ATCC, CCL-1) cell line as healthy control was used. The cells were grown in 5% CO2 at 37°C in DMEM broth (10% FBS, 2mM L-glutamine). ELF-EMF was generated by using a solenoid system. Using IC50 concentration the cells were subjected to ELF-EMF (50 Hz,1 mT) or PTX alone or both for 24 hours. Survival was determined with hemotocytometer. Caspase values are determined by Caspase-8 and Caspase-9 Multiplex Activity kits, Calcium values were determined by Screen Quest FURA-2.Results: IC50 values of PTX for both L-929 and MCF-7 was 7,5 nM. For MCF-7, a reduction in survival of %34,29 (±0,069-STD) for ELF-EMF group, %53,5 (±0,033-STD) for PTX group and %60,19 (±0,088-STD) for both PTX and ELF-EMF application was determined. For L-929 a reduction in survival of %36,25 (±0,018-STD) for ELF-EMF group, %46,27 (±0,115-STD) for PTX group and %65,32 (±0,152-STD) for the group subjected to both PTX and ELF-EMF was observed. Caspase-8 and caspase-9 increased indicating apoptosis as well as calcium in accordance with the decrease of survival.Conclusions: This study showed that ELF-EMF can increase the effectiveness of PTX, which may be promising for future cancer therapy.
Objective: Treatment of breast cancer causes serious side effects which necessitates the investigation of alternative methods. This study aimed to increase the effectiveness of antineoplastic agent Paclitaxel (PTX) by co-application with Extremely Low Frequency Electromagnetic Field (ELF-EMF) that have been shown to induce apoptosis and decrease survival.Materials and Method: Breast cancer cell line MCF-7 (ATCC, HTB-22) and L-929 (ATCC, CCL-1) cell line as healthy control was used. The cells were grown in 5% CO2 at 37°C in DMEM broth (10% FBS, 2mM L-glutamine). ELF-EMF was generated by using a solenoid system. Using IC50 concentration the cells were subjected to ELF-EMF (50 Hz,1 mT) or PTX alone or both for 24 hours. Survival was determined with hemotocytometer. Caspase values are determined by Caspase-8 and Caspase-9 Multiplex Activity kits, Calcium values were determined by Screen Quest FURA-2.Results: IC50 values of PTX for both L-929 and MCF-7 was 7,5 nM. For MCF-7, a reduction in survival of %34,29 (±0,069-STD) for ELF-EMF group, %53,5 (±0,033-STD) for PTX group and %60,19 (±0,088-STD) for both PTX and ELF-EMF application was determined. For L-929 a reduction in survival of %36,25 (±0,018-STD) for ELF-EMF group, %46,27 (±0,115-STD) for PTX group and %65,32 (±0,152-STD) for the group subjected to both PTX and ELF-EMF was observed. Caspase-8 and caspase-9 increased indicating apoptosis as well as calcium in accordance with the decrease of survival.Conclusions: This study showed that ELF-EMF can increase the effectiveness of PTX, which may be promising for future cancer therapy.